Journal of Oncology / 2019 / Article / Tab 3

Research Article

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?

Table 3

Impact of AR/ER and AR/PgR ratios on OS in patients with AR and ER detected both in primary tumor and metastasis (no. 24).

OS (HR) according to best cut-off of the ratios

Primary tumorMetastasis

AR/ER
(cut-off 0.90)
0.33
(95% CI: 0.08 – 1.36)
p = 0.127
0.09
(95% CI: 0.01 - 0.70)
p = 0.022
AR/PgR
(cut-off 0.96)
2.56
(95% CI: 0.56 – 11.72)
p = 0.224
0.53
(95% CI: 0.18 – 1.59)
p = 0.259

Median OS (months) according to AR/ER difference between primary tumor and metastasis

Metastasis

<0.90≥0.90

Primary tumor<0.9032.4
(95% CI: 23.9 - NR)
36.4
(NR)
p=0.011
≥0.9042.2
(95% CI: 14.5 - 87.7)
92.0
(95% CI: 89.4 - NR)

AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio (AR/ER and AR/PgR ratios <cut-off are the reference category); CI, confidence interval; ND, not determinable; NR, not reached.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.